News

July 31, 2020August 3, 2020

Argenx Plans FDA Submission of Efgartigimod by Year’s End

News

Argenx is planning to submit an application to the U.S. Food and Drug Administration (FDA) by the end of this year for its lead candidate, efgartigimod (ARGX-113), for the ... Read more

July 28, 2020July 30, 2020

Case Supports Soliris as Promising Treatment for Thymoma-associated MG

News

Soliris (eculizumab) may be a promising treatment option for patients with refractory myasthenia gravis (MG) associated with a tumor in the thymus gland, a case report suggests. The case ... Read more

July 24, 2020July 31, 2020

Long-term Soliris Therapy Leads to Sustained Muscle Strength Improvement, Studies Show

News

Treatment with Soliris (eculizumab) led to rapid and sustained improvements in muscle strength and the ability to perform daily activities in people with refractory generalized myasthenia gravis (gMG) who ... Read more

July 21, 2020July 21, 2020

Stress and Depression Linked With Relapses in MG Patients

News

Stress and depression are associated with higher relapse rates in people with myasthenia gravis (MG), according to a recent study. Attention to evidence of either disorder is important for ... Read more

July 17, 2020July 17, 2020

Dutch Trial to Test NMD670 Oral Treatment Candidate

News

NMD Pharma is launching a Phase 1/2a trial in the Netherlands to evaluate for the first time NMD670, an oral treatment candidate for people with myasthenia gravis (MG). The ... Read more

July 14, 2020July 14, 2020

Case Report Describes Late-onset MG in Man Treated for Multiple Myeloma

News

A 60-year-old man being treated for multiple myeloma was found to have myasthenia gravis (MG) caused by antibodies against muscle-specific tyrosine kinase (MuSK), a study reports. This unusual case ... Read more

July 13, 2020July 13, 2020

National Survey Seeks to Assess Full Social, Economic Burdens of Rare Diseases in US

News, syndicated

The EveryLife Foundation for Rare Diseases has launched a nationwide National Burden of Rare Disease Survey to measure the full implications, economic and social, of living with rare disease ... Read more

July 10, 2020July 10, 2020

More Severe Disease in MG Patients with LRP4 and Agrin Autoantibodies, Study Finds

News

People with myasthenia gravis who have autoantibodies targeting the proteins LRP4 and agrin have more severe disease compared to patients without those antibodies, a study has found. However, regardless ... Read more

July 7, 2020July 7, 2020

3P Biopharmaceuticals and Toleranzia Advance Partnership to Develop TOL2 for MG

News

3P Biopharmaceuticals and Toleranzia are continuing their partnership to develop Toleranzia’s potential therapy candidate, TOL2, for people living with myasthenia gravis (MG). “Currently there are enormous opportunities offered by biotechnology ... Read more

June 30, 2020June 30, 2020

Immunovant Prepares to Launch Phase 3 Trial of IMVT-1401 in MG Patients

News

Immunovant is preparing to launch a Phase 3 trial of its investigational candidate IMVT-1401 in patients with myasthenia gravis (MG); it may lead to the treatment’s approval for this indication, ... Read more

Pin It on Pinterest